



NSGO-CTU

Nordic Society of Gynaecological Oncology - Clinical Trial Unit

PROGRAM

NSGO-CTU Investigator Meeting 24th – 25th November 2022



Copenhagen, Denmark

Scandic Kødbyen

Skelbækgade 3A

1717 Copenhagen V

Wednesday 23 November 2022

14:00–16:00 **NSGO Board Meeting** (closed meeting)

Meeting Room 10 + 11

16:00–17:30 **NSGO-CTU Scientific Committee Meeting** (closed meeting)

Meeting Room 10 + 11

17:45–19:00 **NSGO Media Group Meeting** (closed meeting)

Meeting Room 10 + 11

Thursday 24 November 2022

08:15–09:00 **NSGO-CTU Foundation Meeting** (closed meeting)

Meeting Room 6

09:30–09:50 **Welcome by Medical Director**

Ballroom 1 + 2

Future plans and status report of NSGO-CTU activities

[Mansoor Raza Mirza](#)

10:00–11:05 **Translational Research session**

Chairs: [Line Bjørge & Anniina Färkkilä](#)

Ballroom 1 + 2

10:00–10:30 **The importance of preclinical models and value of trial samples in translational research**

[Frédéric Amant](#)

10:30–10:45 **Road to precision oncology in ovarian cancer – experiences from the TOPACIO trial.**

[Anniina Färkkilä](#)

10:45–11:00 **Translational work at NSGO-CTU – experiences from the UMBRELLA trial**

High-Dimensional Analysis of Translational Samples from the NSGO-OV-UMB1 UMBRELLA Clinical Trial of Combined Anti-CD73 and Anti-PD-L1 Immunotherapy in Ovarian Cancer

[Luka Tandarić](#)

11:00–11:05 **Closing session**

11:05–12:25 NSGO-CTU-HERO Investigator Meeting

(closed meeting – exhibition is open for the remaining attendees)
Characterization of High-Grade Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype – A Prospective Observational Study
Mansoor Raza Mirza, Signe Gybel Frederiksen & Nicole Buchner Vinum

12:25–13:25 LUNCH

Restaurant MØR

13:25–14:00 OVARIAN CANCER – surgical trials

Chair: Berit Mosgaard

Ballroom 1 + 2

13:30–13:37 **AGO-OVAR OP.7/AGO-OVAR 19/TRUST**
Trial on Radical Upfront Surgery in Advanced Ovarian Cancer
Päivi Kannisto

13:37–13:47 **ENGOT-OV52/OVHIPEC-2**
Phase III randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy
Berit Mosgaard

13:47–14:00 **DISCUSSION**
Päivi Kannisto
Marta Lomnytska
Kristina Lindemann
Titta Joutsiniemi

14:00–15:20 ENGOT-OV56/NSGO-CTU-DOVACC Investigator Meeting

(closed meeting – exhibition is open for the remaining attendees)
A Randomized Clinical Trial Investigating Olaparib, Durvalumab and UV1 as Maintenance Therapy in BRCAwt Patients with Relapsed Ovarian Cancer.

Chair: Mansoor Raza Mirza

Ballroom 1 + 2

14:05–14:20 **Enabling the immune system to fight cancer**
Jens Bjørheim

14:20–14:50 **Study rationale and status**
Mansoor Raza Mirza, Christel Johanneson Bertolt, Kirsten Pors & Signe Gybel Frederiksen

14:50–15:20 **Discussion**

15:20–15:40 BREAK & EXHIBITION

Ballroom 3

15:40–17:00 ENDOMETRIAL CANCER

Chair: Trine Zeeberg Iversen

Ballroom 1 + 2

15:45–15:50 **ENGOT-EN2-DGCG**
A phase III Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high-risk endometrial cancer
Nicoline Raaschou-Jensen

15:50–15:55 **ENGOT-EN1/NSGO-FANDANGO**
A Randomized Phase II Trial of First-line Combination Chemotherapy with Nintedanib/Placebo for Patients with Advanced or Recurrent Endometrial Cancer
Johanna Mäenpää

15:55–16:02 **ENGOT-EN11**
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination with Adjuvant Chemotherapy with or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery with Curative Intent
Ingvild Vistad

16:02–16:10 **ENGOT-EN6/NSGO-RUBY part 1 + 2**
A Phase 3 Randomized Open-Label Study of TSR-042, an anti-PD-1 Mono-clonal Antibody, Versus Investigator's Choice Chemotherapy in Advanced/Recurrent Endometrial Cancer
Mansoor Raza Mirza

16:10-16:17 ENGOT-EN10/DUO-E

A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer

[Karin Grišan](#)

16:17-16:24 ENGOT-EN15/KEYNOTE-C93

A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting

[Susanne Malander](#)

16:24-16:35 ENGOT-EN3/NSGO-PALEO

A randomized, double-blind, placebo controlled, phase II trial of Palbociclib in combination with Letrozole versus Placebo in combination with Letrozole for patients with Estrogen Receptor Positive advanced or recurrent Endometrial cancer

[Mansoor Raza Mirza](#)

ENGOT-EN17

A Multiregional, Randomized, Double Blinded, Placebo Controlled Phase 3 Study of Lerociclib with Letrozole , versus Placebo with Letrozole, in pts with Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrioid Endometrial Carcinoma

[Mansoor Raza Mirza](#)

16:35-17:00 DISCUSSION

[Nicoline Raaschou-Jensen](#)

[Johanna Mäenpää](#)

[Ingvild Vistad](#)

[Karin Grišan](#)

[Susanne Malander](#)

[Mansoor Raza Mirza](#)

[Katrín Kristjánsdóttir](#)

17:00-17:30 How to foster clinical trials in NSGO-CTU

Ballroom 1 + 2

[Kristina Lindemann](#)

17:30-17:40 PEACE trial

Ballroom 1 + 2

Palliation in gynae-oncology: Evaluation and Assessment of satisfaction with care

[Kristina Lindemann](#)

**18:00-21:30 NSGO-CTU Scientific Satellite Symposium:
Long-term benefit of PARP inhibitors**

Chair: [Mansoor Raza Mirza & Line Bjørge](#)

Ballroom 1 + 2

The Symposium is supported with an educational grant from AstraZeneca

Restaurant MØR

18:00-19:30 DINNER

19:30-19:35 Introduction

[Mansoor Raza Mirza & Line Bjørge](#)

19:35-20:05 Role of maintenance therapy in ovarian cancer

[Jalid Sehouli](#)

20:05-20:25 First-line maintenance therapy – changing the landscape

[Mansoor Raza Mirza](#)

20:25-20:45 The best placement of PARP inhibitors – firstline, platinum-sensitive relapse or after multiple relapses

[Jonathan Ledermann](#)

20:45-21:30 Discussion

Please evaluate the day by scanning the below QR code with your mobile camera and open the link:



Friday 25 November 2022

08:00-08:50 CERVICAL CANCER

Chair: [Kristina Lindemann](#)

Ballroom 1 + 2

08:05-08:15 **ENGOT-CX11/KEYNOTE-A18**

A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer

[Elisabeth Berge Nilsen](#)

08:15-08:25 **ENGOT-CX10/GEICO 68-C/BEATcc**

A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent or Recurrent Carcinoma of the Cervix

[Kristina Lindemann](#)

08:25-08:35 **ENGOT-CX6**

A Single arm, Multicenter, Phase 2b Trial Investigating the Efficacy of Tisotumab Vedotin (HuMax®-TF-ADC) Therapy in Previously treated Patients with Recurrent or Metastatic Cervical Cancer

[Kristine Madsen](#)

ENGOT-CX8/GCT1015-05

Randomized, open label, phase 1b/2 first line trial with Tisotumab Vedotin

[Kristine Madsen](#)

ENGOT-CX12

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer

[Kristine Madsen](#)

08:35-08:50 **DISCUSSION**

[Elisabeth Berge Nilsen](#)

[Kristina Lindemann](#)

[Kristine Madsen](#)

[Mari Bunkholt Elstrand](#)

[Synnöve Staff](#)

[Bente Vilming](#)

08:50-10:10 OVARIAN CANCER – first line**Chair: Kristine Madsen***Ballroom 1 + 2***08:55-09:02 AGO-OVAR 17/BOOST**

A prospective randomized Phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in patients with primary epithelial ovarian, fallopian tube or peritoneal cancer

Hanna Dahlstrand**09:02-09:09 ENGOT-OV25/PAOLA-1**

Randomised, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV High Grade Serous or Endometrioid Cancer, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance

Trine Jakobi Nøttrup**09:09-09:16 ENGOT-OV26/PRIMA**

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Anja Ør Knudsen**09:16-09:23 ENGOT-OV44/FIRST**

An adaptive Randomized Phase III Comparison of Standard Platinum Based Treatment Versus Platinum and TSR-042 followed by Niraparib and TSR-042 maintenance Therapy in Patients with epithelial Stage III or IV Cancer of the Ovary, Fallopian Tube, or Peritoneum

Annika Auranen**09:23-09:30 ENGOT-OV46/DUO-0**

Phase III Randomized, Double Blind, Placebo Controlled, Multicentre Study of durvalumab in combination with chemotherapy and bevacizumab followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer patients

Lars Fokdal

09:30-09:37 ENGOT-OV45/ATHENA

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment following Response to Front-Line Platinum-Based Chemotherapy

[Gabriel Lindahl](#)

09:37-09:47 NSGO-CTU-HERO

Characterization of High-Grade Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype – A Prospective Observational Study

[Anniina Färkkilä](#)

08:47-10:10 DISCUSSION

[Hanna Dahlstrand](#)

[Trine Jakobi Nøttrup](#)

[Anja Ør Knudsen](#)

[Annika Auranen](#)

[Lars Fokdal](#)

[Gabriel Lindahl](#)

[Anniina Färkkilä](#)

[Olesya Solheim](#)

10:10-10:30 BREAK & EXHIBITION

Ballroom 3

10:30-11:50 OVARIAN CANCER – platinum is an option

Chair: [Gabriel Lindahl](#)

Ballroom 1 + 2

10:35-10:45 ENGOT-OV16/NOVA

A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer

[Mansoor Raza Mirza](#)

10:45-10:52 ENGOT-OV38/OreO

A Phase IIIb, randomised, double-blind, placebo-controlled, multicentre study of olaparib maintenance retreatment in patients with epithelial ovarian cancer previously treated with a PARPi and responding to repeat platinum chemotherapy

[Henrik Roed](#)

10:52-11:02 **ENGOT-OV71/UP-NEXT**

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent, Platinum-Sensitive Ovarian Cancer

[Susanne Malander](#)

11:02-11:12 **ENGOT-OV56/DOVACC**

A Randomized Clinical Trial Investigating Olaparib, Durvalumab and UV1 as Maintenance Therapy in BRCAwt Patients with Relapsed Ovarian Cancer

[Josefin Fernebro](#)

11:12-11:32 **KANDOVA**

A two-part Phase Ib/IIa study to evaluate the safety and tolerability of KAND567 in combination with carboplatin therapy and to determine the Recommended Phase II Dose (RPIID). An open-label, multicenter dose escalation study with an expansion cohort in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

[Hanna Dahlstrand](#)

11:32-11:50 **DISCUSSION**

[Mansoor Raza Mirza](#)

[Henrik Roed](#)

[Susanne Malander](#)

[Josefin Fernebro](#)

[Hanna Dahlstrand](#)

[Elina Urpilainen](#)

[Ane Gerda Zahl Eriksson](#)

[Kristiina Ojamaa](#)

**12:00-15:00 NSGO-CTU Scientific Satellite Symposium:
Advances in the treatment of cervical cancer**

Chair: [Trine Jakobi Nøttrup](#) & [Kristina Lindemann](#)

Ballroom 1 + 2 The Symposium is supported with an educational grant from MSD

Restaurant MØR 12:00-13:00 **LUNCH**

13:00-13:05 **Introduction**

[Trine Jakobi Nøttrup](#) & [Kristina Lindemann](#)

13:05-13:25 **Advances in surgical treatment**

[Fabrice Lecuru](#)

13:25-13:45 **Role of immunotherapy in cervical cancer**

[Kristina Lindemann](#)

13:45-14:05 **Beyond immunotherapy – targeted agents in the horizon**

[Kristine Madsen](#)

14:05-15:00 **Discussion**

15:00-15:20 BREAK & EXHIBITION

Ballroom 3

15:20-16:20 OVARIAN CANCER – platinum is not an option

Chair: [Annika Auranen](#)

Ballroom 1 + 2

15:25-15:32 **AGO-OVAR 2.29/ENGOT-OV34**

Atezolizumab in combination with Bevacizumab and Chemotherapy versus Chemo-Bevacizumab standard in recurrent ovarian cancer – a randomized Phase III trial

[Goda Jonuškienė](#)

15:32-15:42 **ENGOT-OV68/ARTISTRY-7**

A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

[Liv Cecilie Vestrheim Thomsen](#)

15:42-15:49 **EPIK-0**

A Phase III randomized study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib in patients with no germline BRCA mutation detected, platinum-resistant or refractory, high grade serous ovarian cancer

[Farrukh Chaudhary](#)

15:49-15:56 **UP-LIFT**

A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express Na-Pi2b

[Birute Brasiūnienė](#)

15:56-16:03 **ENGOT-OV65/KEYNOTE-B96**

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

[Heini Lassus](#)

16:03-16:20 **DISCUSSION**

[Goda Jonuškienė](#)

[Liv Cecilie Vestrheim Thomsen](#)

[Farrukh Chaudhary](#)

[Birute Brasiūnienė](#)

[Heini Lassus](#)

16:20-16:25 Closing remarks

Ballroom 1 + 2

[Mansoor Raza Mirza](#)

Please evaluate the day and the meeting in general by scanning the below QR codes with your mobile camera and open the link:



This meeting is sponsored by:

AstraZeneca 



GSK

